CN111821261B - 用于制备无菌眼用水性丙酸氟替卡松a型纳米晶体混悬液的方法 - Google Patents

用于制备无菌眼用水性丙酸氟替卡松a型纳米晶体混悬液的方法 Download PDF

Info

Publication number
CN111821261B
CN111821261B CN202010707466.0A CN202010707466A CN111821261B CN 111821261 B CN111821261 B CN 111821261B CN 202010707466 A CN202010707466 A CN 202010707466A CN 111821261 B CN111821261 B CN 111821261B
Authority
CN
China
Prior art keywords
fluticasone propionate
nanosuspension
nanocrystals
aqueous
phase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202010707466.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN111821261A (zh
Inventor
J-M·布科夫斯基
A·纳德卡尔尼
J·L·波伊尔
B·杜克斯罗瓦-查克罗恩
T·纳夫拉蒂尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nikos Eye Medicine
Original Assignee
Nikos Eye Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nikos Eye Medicine filed Critical Nikos Eye Medicine
Priority to CN202210807241.1A priority Critical patent/CN115120557B/zh
Publication of CN111821261A publication Critical patent/CN111821261A/zh
Application granted granted Critical
Publication of CN111821261B publication Critical patent/CN111821261B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nanotechnology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
CN202010707466.0A 2019-07-23 2020-07-21 用于制备无菌眼用水性丙酸氟替卡松a型纳米晶体混悬液的方法 Active CN111821261B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210807241.1A CN115120557B (zh) 2019-07-23 2020-07-21 用于制备无菌眼用水性丙酸氟替卡松a型纳米晶体混悬液的方法

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962877599P 2019-07-23 2019-07-23
US62/877599 2019-07-23
US201962942551P 2019-12-02 2019-12-02
US62/942551 2019-12-02

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210807241.1A Division CN115120557B (zh) 2019-07-23 2020-07-21 用于制备无菌眼用水性丙酸氟替卡松a型纳米晶体混悬液的方法

Publications (2)

Publication Number Publication Date
CN111821261A CN111821261A (zh) 2020-10-27
CN111821261B true CN111821261B (zh) 2022-07-26

Family

ID=71738074

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202010707466.0A Active CN111821261B (zh) 2019-07-23 2020-07-21 用于制备无菌眼用水性丙酸氟替卡松a型纳米晶体混悬液的方法
CN202210807241.1A Active CN115120557B (zh) 2019-07-23 2020-07-21 用于制备无菌眼用水性丙酸氟替卡松a型纳米晶体混悬液的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202210807241.1A Active CN115120557B (zh) 2019-07-23 2020-07-21 用于制备无菌眼用水性丙酸氟替卡松a型纳米晶体混悬液的方法

Country Status (23)

Country Link
US (3) US11406596B2 (https=)
EP (1) EP3769753B1 (https=)
JP (2) JP7021301B2 (https=)
KR (1) KR20220038443A (https=)
CN (2) CN111821261B (https=)
AU (1) AU2020317084A1 (https=)
CA (1) CA3145055A1 (https=)
CY (1) CY1124930T1 (https=)
DK (1) DK3769753T3 (https=)
ES (1) ES2905793T3 (https=)
HR (1) HRP20220165T1 (https=)
HU (1) HUE057416T2 (https=)
LT (1) LT3769753T (https=)
MD (1) MD3769753T2 (https=)
MX (1) MX420447B (https=)
PH (1) PH12022550003A1 (https=)
PL (1) PL3769753T3 (https=)
PT (1) PT3769753T (https=)
RS (1) RS62932B1 (https=)
SI (1) SI3769753T1 (https=)
SM (1) SMT202200082T1 (https=)
TW (1) TWI864053B (https=)
WO (1) WO2021014348A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2905793T3 (es) * 2019-07-23 2022-04-12 Nicox Ophthalmics Inc Procedimiento para la preparación de suspensiones acuosas estériles oftálmicas de nanocristales de propionato de fluticasona de Forma A
CN115554238A (zh) * 2022-10-25 2023-01-03 苏州欧康维视生物科技有限公司 眼用混悬液及其制备方法
CN115887372A (zh) * 2022-10-25 2023-04-04 苏州欧康维视生物科技有限公司 丙酸氟替卡松混悬液及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993021903A1 (en) * 1992-05-06 1993-11-11 Alcon Laboratories, Inc. Use of borate-polyol complexes in ophthalmic compositions
CN101155605A (zh) * 2005-04-11 2008-04-02 眼力健有限公司 作为缓冲体系的硼酸盐-多元醇混合物
CN104350063A (zh) * 2012-05-08 2015-02-11 埃塞克斯治疗公司 疏水性治疗剂的制剂、其制备方法及应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3450805B2 (ja) * 2000-08-08 2003-09-29 わかもと製薬株式会社 水性医薬組成物
US6900184B2 (en) * 2003-04-14 2005-05-31 Wyeth Holdings Corporation Compositions containing pipercillin and tazobactam useful for injection
US8010032B2 (en) * 2005-05-23 2011-08-30 Xerox Corporation Fuser member comprising deflocculated material
WO2010141834A1 (en) 2009-06-05 2010-12-09 Aciex Therapeutics, Inc. Ophthalmic formulations of fluticasone and methods of use
TWI489997B (zh) 2009-06-19 2015-07-01 Alcon Res Ltd 含有硼酸－多元醇錯合物之水性藥學組成物
US20130065888A1 (en) * 2011-08-15 2013-03-14 Biserka Cetina-Cizmek Ophthalmic formulations and processes for their preparation
US9675624B2 (en) * 2012-12-17 2017-06-13 Glaxo Group Limited Combination of levocabastine and fluticasone furoate for the treatment of inflammatory and/or allergic conditions
TWI773641B (zh) 2015-05-08 2022-08-11 日商活效製藥股份有限公司 含有糖皮質類固醇（ｇｌｕｃｏｃｏｒｔｉｃｏｉｄｓ）之奈米微粒子之水性懸浮液劑
ES2905793T3 (es) * 2019-07-23 2022-04-12 Nicox Ophthalmics Inc Procedimiento para la preparación de suspensiones acuosas estériles oftálmicas de nanocristales de propionato de fluticasona de Forma A

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993021903A1 (en) * 1992-05-06 1993-11-11 Alcon Laboratories, Inc. Use of borate-polyol complexes in ophthalmic compositions
CN101155605A (zh) * 2005-04-11 2008-04-02 眼力健有限公司 作为缓冲体系的硼酸盐-多元醇混合物
CN104350063A (zh) * 2012-05-08 2015-02-11 埃塞克斯治疗公司 疏水性治疗剂的制剂、其制备方法及应用

Also Published As

Publication number Publication date
HUE057416T2 (hu) 2022-05-28
MD3769753T2 (ro) 2022-04-30
DK3769753T3 (da) 2022-01-31
CN115120557A (zh) 2022-09-30
KR20220038443A (ko) 2022-03-28
EP3769753B1 (en) 2021-11-17
ES2905793T3 (es) 2022-04-12
PH12022550003A1 (en) 2022-11-14
RS62932B1 (sr) 2022-03-31
JP7494230B2 (ja) 2024-06-03
CA3145055A1 (en) 2021-01-28
US20220323352A1 (en) 2022-10-13
WO2021014348A1 (en) 2021-01-28
JP2021017449A (ja) 2021-02-15
LT3769753T (lt) 2022-05-10
JP2022062172A (ja) 2022-04-19
MX2022000928A (es) 2022-02-22
TW202116326A (zh) 2021-05-01
JP7021301B2 (ja) 2022-02-16
US11406596B2 (en) 2022-08-09
US20210023001A1 (en) 2021-01-28
SI3769753T1 (sl) 2022-04-29
PT3769753T (pt) 2022-02-15
MX420447B (es) 2025-02-10
AU2020317084A1 (en) 2022-03-03
CN115120557B (zh) 2024-05-07
HRP20220165T1 (hr) 2022-04-29
CY1124930T1 (el) 2023-01-05
US20220241296A1 (en) 2022-08-04
PL3769753T3 (pl) 2022-04-04
TWI864053B (zh) 2024-12-01
SMT202200082T1 (it) 2022-03-21
CN111821261A (zh) 2020-10-27
EP3769753A1 (en) 2021-01-27

Similar Documents

Publication Publication Date Title
EP2847207B1 (en) Fluticasone propionate nanocrystals
JP5558582B2 (ja) 眼科用医薬組成物の調製方法
JP2019535798A (ja) 眼科用活性医薬成分送達のためのシクロデキストリン固体複合体の製造
JP7494230B2 (ja) 無菌眼用水性プロピオン酸フルチカゾンａ型ナノ結晶懸濁液の調製方法
CN107847432A (zh) D2o稳定化的药物制剂
WO2018036522A1 (zh) 羊毛甾醇类化合物眼用制剂
JP2022538659A (ja) 薬剤を含む水性組成物のｐＨを安定化させるための方法
JP2013508420A (ja) 点眼製剤およびその製造方法
EP2941437B1 (en) Polymorphic form c of trimacinolone acetonide
HK40077423A (en) Process for the preparation of sterile ophthalmic aqueous fluticasone propionate form a nanocrystals suspensions
HK40077423B (zh) 用於制备无菌眼用水性丙酸氟替卡松a型纳米晶体混悬液的方法
HK40038382A (en) Process for the preparation of sterile ophthalmic aqueous fluticasone propionate form a nanocrystals suspensions
HK40038382B (en) Process for the preparation of sterile ophthalmic aqueous fluticasone propionate form a nanocrystals suspensions
EP2827838B1 (en) Ophthalmic pharmaceutical composition containing a carbonic anhydrase inhibitor and method for the preparation thereof
CN106714803A (zh) 眼用混悬液制剂
KR102271247B1 (ko) 안과용 현탁액 조성물의 제조방법
WO2022195382A1 (en) A stable ophthalmic nanosupension of brinzolamide
HK1233540B (zh) 眼用混悬液制剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40038382

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant